Drug Trial Radar · NCT05695508
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Last checked: Nov 20, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Dec 1, 2022
Primary completion
Sep 15, 2028
Study completion Sep 15, 2029
Sponsor
- Lead sponsor
- University of Heidelberg Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Janssen Research & Development, LLC; Deutsche Studiengruppe Multiples Myelom (DSMM)
- First posted
- Jan 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab
Conditions
- Multiple Myeloma
Interventions
Teclistamab (Tec)Drug
Subcutaneous administration of Teclistamab
DaratumumabDrug
Subcutaneous administration of Daratumumab
DexamethasoneDrug
administered i.v. or orally
LenalidomideDrug
Administration oral
BortezomibDrug
Subcutaneous administration
TalquetamabDrug
Subcutaneous administration of Daratumumab
JNJ-79635322Drug
Subcutaneous administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- number of incidence and severity of adverse events [safety and tolerability]Time frame: through study completion, up to 28 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Charité University Medicin Berlin
Berlin, Germany · Recruiting
Clinic Chemnitz gGmbH
Chemnitz, Germany · Recruiting
University Clinic Technical University Dresden
Dresden, Germany · Recruiting
University Clinic Düsseldorf
Düsseldorf, Germany · Recruiting
University Clinic Freiburg
Freiburg im Breisgau, Germany · Recruiting
Hamburg University Clinic Eppendorf
Hamburg, Germany · Recruiting
Asklepios Clinic Hamburg Altona
Hamburg, Germany · Recruiting
University Hospital Heidelberg
Heidelberg, Germany · Recruiting
University Clinic Schleswig-Holstein Campus Kiel
Kiel, Germany · Recruiting
Technical University Munich
Munich, Germany · Recruiting
University Würzburg
Würzburg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.